Aditya Bagrodia

Even back to trainee, you know, how you thought about post-prostatectomy, biochemical recurrence to now. And that's a huge question. So, you know, don't overthink it.

Totally. And, you know, if I may, like early on, like as like a resident, like seeing somebody in clinic who had like a biochemical recurrence, I was like so freaked out. I was like, this is like nothing could be worse. Like it dreaded the conversation. It was just like, so you felt like the patients are just... living and dying by those PSAs. And, you know, I imagine it was somewhat similar.

Totally. And, you know, if I may, like early on, like as like a resident, like seeing somebody in clinic who had like a biochemical recurrence, I was like so freaked out. I was like, this is like nothing could be worse. Like it dreaded the conversation. It was just like, so you felt like the patients are just... living and dying by those PSAs. And, you know, I imagine it was somewhat similar.

Totally. And, you know, if I may, like early on, like as like a resident, like seeing somebody in clinic who had like a biochemical recurrence, I was like so freaked out. I was like, this is like nothing could be worse. Like it dreaded the conversation. It was just like, so you felt like the patients are just... living and dying by those PSAs. And, you know, I imagine it was somewhat similar.

This is in an era to sound like a dinosaur where, you know, certainly everybody with grade group two disease got treated, still plenty of prostatectomies for grade group one disease. So there's probably been a shift in biology. But, you know, Bogrodia circa 2010 was freaked out. Then Bogrodia was more like, okay, everything's going to be okay.

This is in an era to sound like a dinosaur where, you know, certainly everybody with grade group two disease got treated, still plenty of prostatectomies for grade group one disease. So there's probably been a shift in biology. But, you know, Bogrodia circa 2010 was freaked out. Then Bogrodia was more like, okay, everything's going to be okay.

This is in an era to sound like a dinosaur where, you know, certainly everybody with grade group two disease got treated, still plenty of prostatectomies for grade group one disease. So there's probably been a shift in biology. But, you know, Bogrodia circa 2010 was freaked out. Then Bogrodia was more like, okay, everything's going to be okay.

And now, 10 years into practice-ish, the people that we're operating on are such higher risk, generally speaking, that I might be coming full circle to...

And now, 10 years into practice-ish, the people that we're operating on are such higher risk, generally speaking, that I might be coming full circle to...

And now, 10 years into practice-ish, the people that we're operating on are such higher risk, generally speaking, that I might be coming full circle to...

semi not freaked out but you know biochemical occurrences aren't just like oh this is nothing don't sweat so and yes you know of course adjuvant for all practical purposes outside of like you know maybe young node positive particularly offensive scenarios as as fallen by the wayside So I think a lot of this, this kind of resonates what you're saying and well, let's, let's jump into it.

semi not freaked out but you know biochemical occurrences aren't just like oh this is nothing don't sweat so and yes you know of course adjuvant for all practical purposes outside of like you know maybe young node positive particularly offensive scenarios as as fallen by the wayside So I think a lot of this, this kind of resonates what you're saying and well, let's, let's jump into it.

semi not freaked out but you know biochemical occurrences aren't just like oh this is nothing don't sweat so and yes you know of course adjuvant for all practical purposes outside of like you know maybe young node positive particularly offensive scenarios as as fallen by the wayside So I think a lot of this, this kind of resonates what you're saying and well, let's, let's jump into it.

I mean, first things first, when you're sitting down talking about surgery with the patient, did you bring this up or, or what's your kind of style on this Todd?

I mean, first things first, when you're sitting down talking about surgery with the patient, did you bring this up or, or what's your kind of style on this Todd?

I mean, first things first, when you're sitting down talking about surgery with the patient, did you bring this up or, or what's your kind of style on this Todd?

And when you talk to patients on the front end and you're talking about the efficacy, do you use words like cure just out of curiosity or, you know, what do you actually say to the patient?

And when you talk to patients on the front end and you're talking about the efficacy, do you use words like cure just out of curiosity or, you know, what do you actually say to the patient?

And when you talk to patients on the front end and you're talking about the efficacy, do you use words like cure just out of curiosity or, you know, what do you actually say to the patient?

Yeah, no, spot on. I mean, like for one of the areas that I have some interest in is testis cancer, and it's kind of nice. You can tell a patient, you know, two years into a pretty good deep sigh of relief and, you know, 95% of recurrences will come in.